Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130702 | 0.81 | PI4KA (0.56) | PDE2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL55774 | 0.81 | PDE2A (0.64) | PDE2AGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL18343699 | 0.79 | PDE2A (0.49) | PDE2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31106964 | 0.78 | PDE2A (0.47) | PDE2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24954062 | 0.78 | PDE2A (0.47) | PDE2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31403622 | 0.77 | ADORA2A (0.46) | ADORA2AADORA1HSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL8221333 | 0.77 | HSP90AA1 (0.52) | ADORA2AADORA1HSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL8418316 | 0.76 | ADORA2A (0.42) | ADORA2AADORA1HSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL29950508 | 0.76 | PDE2A (0.43) | PDE2AHSP90AA1GAAALDH1A1KMT2A | |
| SCHEMBL27028464 | 0.76 | PDE2A (0.43) | PDE2AHSP90AA1GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| WO-2023007185-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| CN-108699064-B | Hexahydropyrazino-triazinone derivatives as kinase inhibitors | UCB生物制药私人有限公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3386984-B1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SRL (BE) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-10-22 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | US | disclosed |
| EP-3386984-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-17 | — | — | EP | disclosed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | disclosed |
| WO-2017097871-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-15 | — | — | WO | disclosed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | PDE2A 1357/4885ADORA2A 129/4885ADORA1 545/4885 |
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDE2A 2973/4885ADORA2A 1492/4885ADORA1 1505/4885 |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDE2A 2973/4885ADORA2A 1492/4885ADORA1 1505/4885 |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDE2A 2973/4885ADORA2A 1492/4885ADORA1 1505/4885 |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | TLR3, TLR1, TLR4 | PDE2A 2973/4885ADORA2A 1492/4885ADORA1 1505/4885 |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2B | PDE2A 2580/4885ADORA2A 2512/4885ADORA1 3504/4885 |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2B | PDE2A 2580/4885ADORA2A 2512/4885ADORA1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.